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ABSTRACT
Objectives: Total testosterone/dihydrotestosterone ratio (TT/DHT) was found to determine metabolic risk in polycystic 
ovary syndrome (PCOS). The aim of this study was to analyze whether (TT/DHT) may be helpful in predicting metabolic 
risk not only in PCOS patients but also in healthy women. 
Material and methods: Total testosterone (TT), dihydrotestosterone (DHT), androstendione and dehydroepiandrosterone 
sulphate (DHEA-S) were measured by LC-MS/MS in 36 women with PCOS and in 29 age-matched controls without clinical 
hyperandrogenism. In all participants, anthropometric data, lipids, adipose tissue percent (%fat), HOMA-IR were also assessed. 
Results: The studied groups were not different in terms of age, BMI, waist circumference, %fat and HOMA-IR. In the patients 
group, mean TT and androstendione levels were significantly higher as compared to controls (1.4 nmol/L vs. 1.0 nmol/L, 
P < 0.001) and (6.6 nmol/L vs. 4.9 nmol/L, P < 0.01), respectively. In the patients group, mean TT/DHT ratio was significantly 
higher compared to controls (3.6 vs. 2.7, P < 0.01) and correlated with BMI (r = 0.37, P < 0.05), waist circumference (r = 0.44, 
P < 0.01), %fat (r = 0.30, P < 0.05), as well as with insulin levels (r = 0.38, P < 0.05) and HOMA-IR (r = 0.44, P < 0.05). The as-
sociation between TT/DHT ratio and unfavorable metabolic parameters was also seen in controls.
Conclusion: Total testosterone/dihydrotestosterone ratio assessed by LC-MS/MS correlates with a worse metabolic profile 
not only in PCOS patients, but also in healthy women. 
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) represents the most 
common cause of hyperandrogenism. Based on the clinical 
picture and laboratory findings, three main phenotypes 
of PCOS can be defined: metabolic, hyperandrogenic and 
reproductive [1]. Women with PCOS demonstrate a signifi-
cantly higher prevalence of impaired glucose tolerance and 
noninsulin dependent diabetes, hyperlipidemia, hyperten-
sion, carotid and coronary atherosclerosis, and endothelial 
dysfunction compared with age- and weight-matched con-
trol subjects, which determine increased cardiovascular risk 
in this group of patients [2, 3]. Health providers should focus 
on prophylactic activities, especially in the subgroup of PCOS 
women at higher risk of metabolic complications. Therefore, 
there is the need to identify predictors that would help 
to identify PCOS patients with the highest metabolic risk. 
Münzker et al. proposed total testosterone/dihydrotestos-
terone ratio (TT/DHT) as an indicator of a worse metabolic 
prognosis in PCOS [4]. Metabolic disturbances observed in 
patients with PCOS result from the unfavorable influence of 
androgens on glucose and lipid metabolism as well as on in-
sulin action. In turn, hyperinsulinemia stimulates androgens 
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synthesis in ovaries, closing the vicious circle [5]. Therefore, 
we have aimed at analyzing whether (TT/DHT) may be help-
ful in predicting metabolic risk not only in PCOS patients but 
also in healthy women not meeting PCOS criteria. 
As liquid chromatography coupled with mass spectrom-
etry (LC-MS/MS) is indicated as the method with the highest 
accuracy, we have used this method to measure androgens 
concentrations in order to look for relations between andro-
gen levels, TT/DHT ratio and the metabolic profile in PCOS 
patients and controls [6, 7]. 
MATERIAL AND METHODS 
Subjects 
36 women (18–36 years old, mean age 25.3) with PCOS 
were consecutively recruited from the Department of In-
ternal Medicine and Endocrinology, Medical University of 
Warsaw, between June 2012 and February 2014. The diag-
nosis was established based on Rotterdam ESHRE criteria [1]. 
The control group consisted of 29 healthy women aged 
19–45 years (mean age 27.9) with regular menses, without 
clinical hyperandrogenism (acne and/or androgenic alope-
cia and/or hirsutism and/or virilization). Exclusion criteria for 
both groups were as follows: age < 18 years or > 45 years, 
pregnancy, recent history (up to 3 months) of hormonal 
contraceptive or hormonal replacement therapy use. The 
group was partially described previously [8]. 
All participants have undergone clinical and hormonal 
assessment. Clinical evaluation was based on anthropomet-
ric measurements (including weight, height, waist circum-
ference (WC) and assessment of fat tissue content by the 
bioelectrical impedance method), the data on menstruation 
regularity, presence of clinical hyperandrogenism (hirsutism, 
acne, androgenic alopecia, virilization). Oligoovulation/ano-
vulation was defined by oligomenorrhoea/amenorrhoea. 
Hirsutism was defined by a Ferriman-Gallwey score ≥ 8, pres-
ence of acne and alopecia was recorded but not scored [9]. 
Morphology of ovaries was assessed by pelvic ultrasound.
Biochemical measurements
Laboratory tests consisted of a panel of simultaneously 
measured serum hormones including total testosterone 
(TT), dihydrotestosterone (DHT), dehydroepiandrosterone 
sulphate (DHEA-S) and androstendione as well as sex hor-
mone binding globulin (SHBG), albumin, fasting glucose, 
insulin and lipids. 
The blood samples for hormonal assessment were col-
lected in the morning (7:00–9:00 am) during the early fol-
licular phase of the menstrual cycle (3th–5th day). 
Analysis of albumin concentrations was performed by 
Cobas® diagnostic kits (Roche Diagnostics GmbH, Mannheim, 
Germany), SHBG by ELISA DRG® (DRG Instruments GmbH, 
Marburg, Germany), while serum TT, DHT, androstendione, 
DHEA-S by LC-MS/MS. Free androgen index (FAI) was calcu-
lated according to the formula (TTx100/SHBG).
LC-MS/MS measurements were performed in the Mass 
Spectrometry Laboratory of the Institute of Biochemistry 
and Biophysics, Polish Academy of Sciences. Samples were 
analyzed using Absolute IDQ Stero17 Kit produced by Bio-
crates Life Sciences AG (Innsbruck, Austria) according to the 
validated protocol supplied by the manufacturer. Steroids 
were analyzed in positive ionization (for DHEA-S both positive 
and negative) in multiple reaction monitoring mode [10]. The 
intra- and interassay variability did not exceed 11.5%. 
The project has been approved by the Bioethical Com-
mittee of the Medical University of Warsaw, and written in-
formed consent for participation in this study was obtained 
from all participants. 
Statistical analyses 
The differences in androgens concentrations were as-
sessed with Statistica software package v.10 (StatSoft, Tulsa, 
OK, USA), using paired t test. All correlations between quantita-
tive values were performed with the Pearson correlation test. 
For all tests, the level of significance was established at 0.05.
RESULTS
The basic clinical characteristics of PCOS patients as well 
as the control group are summarized in Table 1.
TT/DHT ratio
Mean TT/DHT ratio in the patients group was signifi-
cantly higher as compared to controls: 3.6 (1.4–7.6) and 
2.7 (1.2–4.9), respectively, P < 0.01. 
TT/DHT ratio correlations 
In the patients group, TT/DHT ratio correlated positively 
with anthropometric parameters: BMI (r = 0.37, P < 0.05), WC 
(r = 0.44, P < 0.01), %fat (r = 0.30, P < 0.05) as well as with in-
sulin level (r = 0.38, P < 0.05) and HOMA-IR (r = 0.44, P < 0.05). 
The positive correlations between TT/DHT and BMI 
(r = 0.50, P<0.01), WC (r = 0.5, P < 0.01), %fat (r = 0.64, P < 0.001), 
insulin level (r = 0.35, P < 0.05) and HOMA-IR (r = 0.41, P < 0.05) 
were also present in the healthy subjects group.
The differences in TT/DHT ratio in terms of BMI, WC, %fat 
and HOMA-IR are presented in Table 2. The ratio was signifi-
cantly higher in PCOS patients and controls, in subgroups 
with greater WC, %fat and HOMA-IR. In controls, significantly 
greater TT/DHT was also detected in terms of BMI. 
Androgens (total testosterone, FAI, DHT, 
androstendione, DHEA-S) 
Mean TT concentration in the patients group (1.4 nmol/L, 
0.7–3.1) was significantly higher as compared to controls 
(1.0 nmol/L, 0.3–1.4), P < 0.001.
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In both groups, TT levels correlated positively with 
HDL-C (r = 0.37, P < 0.05), while no correlations with BMI, 
WC, %FAT, HOMA-IR as well as insulin, total cholesterol (TC) 
and TG levels were detected. 
FAI in the patients group correlated positively with BMI 
(r = 0.35, P < 0.05), WC (r = 0.33, P<0.05), %FAT (r = 0.386, 
P<0.05), HOMA-IR (r = 0.47, P<0.01) and insulin level (r = 0.43, 
P<0.05). In the control group, only the relation with insulin 
(r = 0.57, P<0.01) and HOMA-IR (r = 0.59, P<0.01) was present. 
Mean DHT concentration in the patients group, 0.3 nmol/L 
(0.3-1.4), was not different from controls, 0.3 nmol/L (0.3-1.0). 
No correlations between DHT levels and metabolic param-
eters (BMI, %FAT, insulin, HOMA-IR, TC, HDL-C and TG) were 
detected. Interestingly, DHT correlated negatively with WC 
(r = –0.37, P < 0.05 - the higher WC, the lower DHT). 
Mean androstendione concentration in the patients 
group was significantly higher, 6.6 nmol/L (3.1–12.2), as 
compared to controls, 4.9 nmol/L (1.4–10.1), P < 0.01. 
Mean DHEA-S concentration did not differ significantly 
between the studied groups. No correlation between an-
drostendione and DHEA-S levels and metabolic parameters 
was detected in either studied group.
DISCUSSION
The results of our study showed that TT/DHT ratio cor-
related with a worse metabolic profile not only in PCOS 
patients but also in healthy subjects without hyperandro-
genism. Our finding suggests that TT/DHT ratio may speak 
for metabolic disturbance, not only in PCOS but also in 
“theoretically” healthy subjects without clinical and hormo-
Table 1. Characteristics of studied groups
Patients with HA  
(N = 36)
Controls
(N = 29) P 
Age, years, mean (±SD) 25.3 (±4.7) 27.9 (±7.5) 0.1
BMI, kg/m2, mean (±SD) 25.3 (±7.3) 23.3 (±5.5) 0.4
Waist circumference, cm, mean (±SD) 77.4 (±14.2) 76.2 (±10.9) 0.8
% of adipose tissue* mean (±SD) 32.9 (±8.5) 29.1 (±6.8) 0.1
Insulin, µIU/mL, mean (±SD) 7.4 (±3.2) 6.8 (±4) 0.9
HOMA-IR, mean (±SD) 1.6 (±0.7) 1.57 (±0.9) 0.7
HDL-C, mmol/L, mean (±SD) 2.3 (±1.3) 2.4 (±0.7) 0.3
Triglicerydes, mmol/L, mean (±SD) 0.6 (±0.2) 0.7 (±0.1) 0.7
Metabolic syndrome, n 2 3 0.9
Ferriman-Gallwey score, mean (±SD) 4.7 (±5) 0.59 (±1.6) <0.0001
Acne, n (%) 24 (66.6) 0 <0.0001
Menstrual disturbances, n (%) 25 (69.4) 0 <0.0001
Total testosterone, nmol/L, mean (±SD) 1.4 (±0.7) 1.0 (±0.3) <0.001
FAI, mean (±SD) 2.2 (±1.1) 1.7 (±1.0) <0.05
DHT, nmol/L, mean (±SD) 0.3 (±0.3) 0.3 (±0.3) 0.7
Androstendione, nmol/L, mean (±SD) 6.6 (±2.1) 4.9 (±1.7) <0.01
DHEA-S, µmol/L, mean (±SD) 7.6 (±2.4) 6.9 (±2.5) 0.2
*Measured by the bioelectrical impedance method 
BMI — body mass index, defined as the body mass (kg) divided by the square of the body height (m); DHEA-S — dehydroepiandrosterone sulphate;  
DHT — dihydrotestosterone; FAI — free androgen index; HA — hyperandrogenism; HDL-C — high density lipoprotein cholesterol; HOMA-IR — insulin resistance index; 
n — number 
Table 2. Differences in TT/DHT (total testosterone/dihydrotestosterone) ratio in PCOS patients and controls in terms of BMI, WC, HOMA-IR  
and % of adipose tissue
Parameter Ranges PCOS P Controls P P**
BMI [kg/m2] ≥30 vs. <30 4.3±1.3 vs. 3.4±1.3 0.1 4.3±0.4 vs. 2.6±1.1 0.047 0.1
WC [cm] >80 vs. ≤80 4.4 ± 0.9 vs. 3.3 ± 1.4 0.01 3.9±0.6 vs. 2.5±1.1 0.03 0.36
% of adipose tissue* ≥30 vs. <30  4.9±1.5 vs. 3.2 ±1.1 0.009 3.6±1.5 vs. 2.4±1.0 0.0002 0.11
HOMA-IR ≥2 vs. <2 4.2 ± 1.5 vs. 2.9 ± 0.9 0.01 3.7±0.9 vs. 2.0±0.6 0.04 0.80
*Measured by the bioelectrical impedance method; ** PCOS vs. controls 
BMI — body mass index; WC — waist circumference; HOMA-IR — insulin resistance index 
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nal hyperandrogenism. Moreover, increased TT/DHT ratio 
may be considered as a predictor of development of PCOS 
in this group of women in future. 
Ollila et al. in their large study concluded that symp-
toms or diagnosis of PCOS are associated with dyslipidemia 
and significantly increased weight gain, especially in early 
adulthood [11]. Subsequently, a number of studies were 
conducted in order to identify potential predictors of the 
metabolic risk in this group of patients. Valderhaug et al. 
observed that among obese women, not meeting PCOS 
criteria, those with hyperandrogenemia have a worse 
metabolic phenotype [12]. In other studies, a worse meta-
bolic profile in PCOS patients was associated with higher 
testosterone concentrations [13]. In turn, Li et al. showed 
that higher FAI in patients with PCOS correlates with higher 
BMI, %fat, TC, DHEA-S and HOMA-IR [14]. Recently, Münz-
ker et al. suggested that increased TT/DHT ratio is a good 
predictor of unfavorable metabolic profile in this group of 
patients [4]. The results of our study confirm this hypoth-
esis but also suggest that high TT/DHT ratio can be consid-
ered as a risk factor of metabolic disturbances in women 
without signs or symptoms of PCOS. What is important, 
the control group investigated in our study was not only 
BMI-matched but also did not differ from PCOS patients 
in terms of WC, content of adipose tissue, insulin level 
and HOMA-IR. In the study of Münzker et al., the control 
group differed from the PCOS patients by mean insulin 
levels and HOMA-IR [4]. 
In contrast to TT/DHT ratio, in our control group no cor-
relation between TT alone and metabolic parameters was 
found, while we found a strong relation between FAI and 
insulin/HOMA-IR. This finding can be explained by the influ-
ence of insulin on SHBG level [15]. Moreover, we have not 
observed an association between other androgens levels 
and metabolic profile either in controls or in PCOS patients, 
and this finding is consistent with the results of others [16]. 
The undeniable strength of our study was the applica-
tion of the LC-MS/MS method for steroid measurements 
that assures high accuracy of the obtained results. Another 
strength is careful selection of the control group that was not 
different from the PCOS patients in terms of anthropometric 
parameters as well as insulin concentration and HOMA-IR. 
However, due to the relatively small size of the investigated 
groups, further studies and larger trials are needed to verify 
our results.
CONCLUSIONS 
TT/DHT ratio correlates with a worse metabolic profile 
in PCOS patients but also in healthy women. 
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